CL2015000787A1 - Derivados de 1,2,4-triazina para el tratamiento de infecciones virales. - Google Patents

Derivados de 1,2,4-triazina para el tratamiento de infecciones virales.

Info

Publication number
CL2015000787A1
CL2015000787A1 CL2015000787A CL2015000787A CL2015000787A1 CL 2015000787 A1 CL2015000787 A1 CL 2015000787A1 CL 2015000787 A CL2015000787 A CL 2015000787A CL 2015000787 A CL2015000787 A CL 2015000787A CL 2015000787 A1 CL2015000787 A1 CL 2015000787A1
Authority
CL
Chile
Prior art keywords
treatment
viral infections
triazine derivatives
triazine
tlr8
Prior art date
Application number
CL2015000787A
Other languages
English (en)
Inventor
Vincent Gembus
Philippe Jubault
Christophe Hoarau
Vincent Levacher
Gowan David Graig Mc
Jerome Emile Georges Guillemont
Jean-Francois Bonfanti
Original Assignee
Univ Rouen
Inst Nat Sciences Appliq
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rouen, Inst Nat Sciences Appliq, Centre Nat Rech Scient filed Critical Univ Rouen
Publication of CL2015000787A1 publication Critical patent/CL2015000787A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

COMPUESTOS DERIVADOS DE 1,2,4-TRIAZINA; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO EN EL CUAL LA MODULACION DE TLR7 Y/O TLR8 ESTA IMPLICADA, TAL COMO INFECCIONES VIRALES Y TRASTORNOS INMUNES O INFLAMATORIOS.
CL2015000787A 2012-10-01 2015-03-30 Derivados de 1,2,4-triazina para el tratamiento de infecciones virales. CL2015000787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12306196.2A EP2712866A1 (en) 2012-10-01 2012-10-01 1,2,4-triazine derivatives for the treatment of viral infections

Publications (1)

Publication Number Publication Date
CL2015000787A1 true CL2015000787A1 (es) 2015-10-02

Family

ID=46982496

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000787A CL2015000787A1 (es) 2012-10-01 2015-03-30 Derivados de 1,2,4-triazina para el tratamiento de infecciones virales.

Country Status (21)

Country Link
US (1) US9416114B2 (es)
EP (2) EP2712866A1 (es)
JP (1) JP6298998B2 (es)
KR (1) KR102138393B1 (es)
CN (1) CN104812747B (es)
AU (1) AU2013326579B2 (es)
BR (1) BR112015007310B1 (es)
CA (1) CA2886630C (es)
CL (1) CL2015000787A1 (es)
EA (1) EA026236B1 (es)
ES (1) ES2616496T3 (es)
IL (1) IL237871A (es)
IN (1) IN2015DN03327A (es)
MX (1) MX348229B (es)
MY (1) MY182558A (es)
NZ (1) NZ706354A (es)
PH (1) PH12015500724A1 (es)
SG (1) SG11201502522WA (es)
UA (1) UA114644C2 (es)
WO (1) WO2014053516A1 (es)
ZA (1) ZA201502240B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
UA116083C2 (uk) 2011-11-09 2018-02-12 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні пурину для лікування вірусних інфекцій
PT2872515T (pt) 2012-07-13 2016-07-27 Janssen Sciences Ireland Uc Purinas macrocíclicas para o tratamento de infeções virais
EA035327B1 (ru) 2012-10-10 2020-05-28 Янссен Сайенсиз Айрлэнд Юси Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
ES2655843T3 (es) 2012-11-16 2018-02-21 Janssen Sciences Ireland Uc Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas
MY191389A (en) 2013-02-21 2022-06-22 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
CN105338983B (zh) 2013-03-29 2019-10-25 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
JP6377139B2 (ja) 2013-05-24 2018-08-22 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体
JP6763769B2 (ja) 2013-06-27 2020-09-30 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染症および他の疾病の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体
MX368625B (es) 2013-07-30 2019-10-08 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
SG11201811448RA (en) 2016-07-01 2019-01-30 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines for the treatment of viral infections
KR102450287B1 (ko) * 2016-09-29 2022-09-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
BR112021015577A8 (pt) 2019-02-08 2021-10-05 Research & Business Found Sungkyunkwan Univ Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo
EP4115901A4 (en) 2020-03-02 2024-04-10 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
EP4194010A4 (en) 2020-08-04 2025-03-26 Progeneer Inc. Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof
WO2024151953A1 (en) * 2023-01-15 2024-07-18 Viradem Inc. Compounds and methods for treating diseases caused by sars-cov-2 and other coronaviruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485531A1 (fr) * 1980-06-25 1981-12-31 Fabre Sa Pierre Nouveaux n-oxydes de diaryl-5,6 as triazines 1-2-4, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
TW552261B (en) 1996-07-03 2003-09-11 Japan Energy Corp Novel purine derivative
CA2311742C (en) 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
RU2401833C2 (ru) * 2004-08-10 2010-10-20 Янссен Фармацевтика Н.В. Производные 1, 2, 4-триазин-6-она, ингибирующие вич
MX2007013780A (es) 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
RU2352565C1 (ru) * 2007-10-08 2009-04-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" 3-амино-6-ароилметил-5-гидрокси-1,2,4-триазины и способ их получения
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease

Also Published As

Publication number Publication date
KR20150084791A (ko) 2015-07-22
EA026236B1 (ru) 2017-03-31
CA2886630C (en) 2021-01-26
MY182558A (en) 2021-01-25
AU2013326579A1 (en) 2015-04-09
ES2616496T3 (es) 2017-06-13
SG11201502522WA (en) 2015-05-28
EA201500383A1 (ru) 2015-07-30
UA114644C2 (uk) 2017-07-10
CN104812747A (zh) 2015-07-29
CN104812747B (zh) 2017-03-08
IN2015DN03327A (es) 2015-10-09
BR112015007310A2 (pt) 2017-08-08
JP2015535839A (ja) 2015-12-17
PH12015500724B1 (en) 2015-06-01
BR112015007310B1 (pt) 2022-07-19
US20150336907A1 (en) 2015-11-26
EP2903976B1 (en) 2016-12-07
AU2013326579B2 (en) 2017-04-27
EP2903976A1 (en) 2015-08-12
WO2014053516A1 (en) 2014-04-10
NZ706354A (en) 2018-08-31
PH12015500724A1 (en) 2015-06-01
MX2015004160A (es) 2016-02-05
CA2886630A1 (en) 2014-04-10
HK1208223A1 (en) 2016-02-26
MX348229B (es) 2017-05-31
ZA201502240B (en) 2016-05-25
US9416114B2 (en) 2016-08-16
IL237871A (en) 2017-04-30
EP2712866A1 (en) 2014-04-02
JP6298998B2 (ja) 2018-03-28
KR102138393B1 (ko) 2020-08-14

Similar Documents

Publication Publication Date Title
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
ZA201903161B (en) Antiviral compositions for the treatment of infections linked to coronaviruses
CL2016000381A1 (es) Compuestos antivirales
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
PH12017500207A1 (en) Indoles for use in influenza virus infection
CL2015001265A1 (es) Compuestos derivados de 2-aminoquinazolina sustituidos; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7 y/o tlr8 tal como infecciones viricas.
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2014001205A1 (es) Compuestos derivados de purina, sus sales y solvatos farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tal como infecciones viricas, trastornos inmunitarios o inflamatorios.
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CL2014001956A1 (es) Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas.
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2015002060A1 (es) Compuestos.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.